Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Inclusion Criteria: * 20\~75 years * Histologically or cytologically confirmed solid tumors that have failed to standard therapy or for which no life prolonging treatment exists * ECOG PS 0-2 * Life expectancy 12 weeks * Hematopoietic: ANC ≥ 1,500/mm3, Platelet ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL, Prothrombin time, Activated partial thromboplastin time: normal range * Hepatic: total bilirubin ≤ 1.5×ULN(except Gilbert's syndrome patients), AST, ALT ≤ 3.0×ULN(AST, ALT ≤ 5.0×ULN in case of liver metastases) * Renal: serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min * Signed a written informed consent Exclusion Criteria: * Brain or Leptomeningeal metastases * History of Ischemic heart disease(e.g., myocardial infarction, unstable angina pectoris) or Clinically significant heart disease such as NYHA Class III and IV Congestive atrial arrhythmias, within 6 months prior to first dose of study drug * Stable angina pectoris shown symptoms within 6 months prior to first dose of study durg, or Clinically significant abnormality on EKG or echocardiogram(e.g., LVEF \< 50% or clinically significant heart wall abnormality or heart muscle damage) * Cerebrovascular disease such as stroke * Grade 2 or greater motor or sensory peripheral neuropathy * Clinically significant eye diseases(e.g., Glaucoma or Proliferative diabetic retinopathy, Atrophic macular degeneration), or other clinically significant abnormality on screening visit * Uncontrolled hypertension(greater than 150 mmHg systolic anc 100 mmHg diastolic regardless of medication) * acute infection or blooding tendencies that would preclude study compliance * Serious vascular disease such as Aortic aneurysm * Other psychiatric disorders or other conditions that would preclude study compliance * Receiving anticoagulation with warfarin, heparin, etc. * Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks for radiation therapy) * Other concurrent antitumor therapy * History of Serious hypersensitivity or allergy * Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective contraception * Participation in a clinical trial within 4 weeks of first dose of study drug